Intensive multi-disciplinary care for patients with brain metastases
Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases
NA · University of Vermont Medical Center · NCT06280300
This study is testing if a team-based approach to care for patients with newly diagnosed brain metastases can help them feel better and understand their condition more clearly compared to standard care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Vermont Medical Center (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Burlington, Vermont) |
| Trial ID | NCT06280300 on ClinicalTrials.gov |
What this trial studies
This health services intervention focuses on comparing the effects of intensive multi-disciplinary care (IMDC) against standard care for patients with newly diagnosed brain metastases. The study involves a cohort of patients who will receive either standard of care or IMDC, which includes input from various specialists such as medical oncology, neurosurgery, and palliative care. The aim is to assess the impact of this systematic approach on patient-reported symptoms and prognostic awareness. By ensuring consistent access to multi-disciplinary discussions, the study seeks to improve the overall management of brain metastases.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with newly diagnosed, histologically confirmed brain metastases from solid tumors.
Not a fit: Patients under 18 years of age or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved symptom management and better prognostic understanding for patients with brain metastases.
How similar studies have performed: Other studies have shown that multi-disciplinary approaches can enhance patient outcomes, suggesting potential success for this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of all genders must be at least 18 years of age. * Patients must have histologically confirmed, newly diagnosed brain metastases from known or suspected solid tumor primary neoplasms. * Patients must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact). * Patients must be able to complete questionnaires in English. * Patients must have the ability to provide informed consent. Exclusion Criteria: * Patients who are \< 18 years of age are not eligible. * Patients who are Pregnant are not eligible.
Where this trial is running
Burlington, Vermont
- University of Vermont Medical Center — Burlington, Vermont, United States (RECRUITING)
Study contacts
- Study coordinator: Alissa A Thomas, MD
- Email: athoma21@med.uvm.edu
- Phone: 802-847-8400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Brain Metastases, Adult